Biological CSF Markers of Alzheimer's Disease

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 261-268

  Zetterberg, Henrik ^a   Blennow, Kaj ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; HUMAN; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; TAU PROTEINS;

EID: 66049148147     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01224-9     Document Type: Review

References (77)

1. Andreasen N., Minthon L., Clarberg A., et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53 (1999) 1488-1494
2. Andreasen N., Minthon L., Vanmechelen E., et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 273 (1999) 5-8
3. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
4. Andreasen N., Vanmechelen E., Vanderstichele H., et al. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl 179 (2003) 47-51
5. Arai H., Morikawa Y., Higuchi M., et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236 (1997) 262-264
6. Arai H., Ishiguro K., Ohno H., et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166 (2000) 201-203
7. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1 (2004) 213-225
8. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003) 605-613
9. Blennow K., Wallin A., and Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 88 (1993) 221-223
10. Blennow K., Davidsson P., Wallin A., et al. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int Psychogeriatr 6 (1994) 13-22
11. Blennow K., Wallin A., Agren H., et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 26 (1995) 231-245
12. Buee L., Bussiere T., Buee-Scherrer V., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33 (2000) 95-130
13. Buerger K., Teipel S.J., Zinkowski R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 (2002) 627-629
14. Davidsson P., and Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 21 (2005) 81-92
15. Davies L., Wolska B., Hilbich C., et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 (1988) 1688-1693
16. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2 (2003) 15-21
17. Fukuyama R., Mizuno T., Mori S., et al. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 43 (2000) 155-160
18. Goedert M., Spillantini M.G., Potier M.C., et al. Cloning and sequencing of the cdna encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mrnas in human brain. Embo J 8 (1989) 393-399
19. Gottfries J., Blennow K., Lehmann M.W., et al. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol 14 (2001) 109-114
20. Grundke-Iqbal I., Iqbal K., Tung Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83 (1986) 4913-4917
21. Hesse C., Rosengren L., Vanmechelen E., et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2 (2000) 199-206
22. Holmberg B., Johnels B., Blennow K., et al. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 18 (2003) 186-190
23. Hu Y.Y., He S.S., Wang X., et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : An ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 160 (2002) 1269-1278
24. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
25. Iqbal K., Alonso A.D., Gondal J.A., et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm Suppl 59 (2000) 213-222
26. Iqbal K., Alonso Adel C., El-Akkad E., et al. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration. J Neural Transm Suppl 62 (2002) 309-319
27. Iwatsubo T., Odaka A., Suzuki N., et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 13 (1994) 45-53
28. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
29. Jellinger K.A. Diagnostic accuracy of Alzheimer's disease: A clinicopathological study. Acta Neuropathol (Berl) 91 (1996) 219-220
30. Kanai M., Matsubara E., Isoe K., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann Neurol 44 (1998) 17-26
31. Kosunen O., Soininen H., Paljarvi L., et al. Diagnostic accuracy of Alzheimer's disease: A neuropathological study. Acta Neuropathol (Berl) 91 (1996) 185-193
32. Lautenschlager N.T., Riemenschneider M., Drzezga A., et al. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord 12 (2001) 379-386
33. Lewczuk P., Esselmann H., Meyer M., et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 17 (2003) 1291-1296
34. Maddalena A., Papassotiropoulos A., Muller-Tillmanns B., et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 60 (2003) 1202-1206
35. Maruyama M., Arai H., Sugita M., et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 172 (2001) 433-436
36. Masters C.L., Simms G., Weinman N.A., et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82 (1985) 4245-4249
37. Mathis C.A., Wang Y., and Klunk W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10 (2004) 1469-1492
38. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
39. Mehta P.D., Pirttila T., Mehta S.P., et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57 (2000) 100-105
40. Miller D.L., Papayannopoulos I.A., Styles J., et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301 (1993) 41-52
41. Monte S.M., Ghanbari K., Frey W.H., et al. Characterization of the AD7C-NTP cdna expression in Alzheimer's disease and measurement of a 41-kd protein in cerebrospinal fluid. J Clin Invest 100 (1997) 3093-3104
42. Mori H., Hosoda K., Matsubara E., et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 186 (1995) 181-183
43. Mosconi L., Tsui W.H., De Santi S., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64 (2005) 1860-1867
44. Mrak R.E., and Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26 (2005) 349-354
45. Nishimura T., Takeda M., Nakamura Y., et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: Multicenter study in Japan. Methods Find Exp Clin Pharmacol 20 (1998) 227-235
46. Otto M., Wiltfang J., Tumani H., et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225 (1997) 210-212
47. Otto M., Esselmann H., Schulz-Shaeffer W., et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54 (2000) 1099-1102
48. Otto M., Wiltfang J., Cepek L., et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58 (2002) 192-197
49. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56 (1999) 303-308
50. Pratico D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: The road ahead. Neurobiol Aging 26 (2005) 581-583
51. Prince J.A., Zetterberg H., Andreasen N., et al. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62 (2004) 2116-2118
52. Riemenschneider M., Lautenschlager N., Wagenpfeil S., et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59 (2002) 1729-1734
53. Riemenschneider M., Wagenpfeil S., Diehl J., et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58 (2002) 1622-1628
54. Riemenschneider M., Wagenpfeil S., Vanderstichele H., et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 8 (2003) 343-347
55. Rosengren L.E., Karlsson J.E., Sjogren M., et al. Neurofilament protein levels in CSF are increased in dementia. Neurology 52 (1999) 1090-1093
56. Selkoe D.J. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81 (2001) 741-766
57. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
58. Sergeant N., Bombois S., Ghestem A., et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J Neurochem 85 (2003) 1581-1591
59. Seubert P., Vigo-Pelfrey C., Esch F., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
60. Shoji M., Matsubara E., Kanai M., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158 (1998) 134-140
61. Sjogren M., Minthon L., Davidsson P., et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 107 (2000) 563-579
62. Sjogren M., Blomberg M., Jonsson M., et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 66 (2001) 510-516
63. Sjogren M., Davidsson P., Gottfries J., et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 12 (2001) 257-264
64. Sjogren M., Davidsson P., Wallin A., et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 13 (2002) 112-118
65. Skoog I., Davidsson P., Aevarsson O., et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15 (2003) 169-176
66. Strozyk D., Blennow K., White L.R., et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
67. Sunderland T., Linker G., Mirza N., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
68. Tamaoka A., Kondo T., Odaka A., et al. Biochemical evidence for the long-tail form (Abeta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 205 (1994) 834-842
69. Vandermeeren M., Mercken M., Vanmechelen E., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61 (1993) 1828-1834
70. Vanderstichele H., De Meyer G., Andreasen N., et al. Amino-truncated {beta}-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin Chem 51 (2005) 1650-1660
71. Van Everbroeck B., Quoilin S., Boons J., et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74 (2003) 1210-1214
72. Vigo-Pelfrey C., Lee D., Keim P., et al. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 61 (1993) 1965-1968
73. Vigo-Pelfrey C., Seubert P., Barbour R., et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45 (1995) 788-793
74. Wang G.P., Khatoon S., Iqbal K., et al. Brain ubiquitin is markedly elevated in Alzheimer disease. Brain Res 566 (1991) 146-151
75. Wiltfang J., Esselmann H., Bibl M., et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 81 (2002) 481-496
76. Yao Y., Clark C.M., Trojanowski J.Q., et al. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58 (2005) 623-626
77. Zetterberg H., Wahlund L.O., and Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352 (2003) 67-69